乳腺癌管理迫切需要及时、准确的决策。本叙述性综述旨在阐明新型 PET 示踪剂在优化不同乳腺癌亚型治疗策略中的潜在作用。2-脱氧-2-[18F]-氟-D-葡萄糖 PET/计算机断层扫描 (FDG PET/CT) 具有尽管其在某些组织学和分子亚型方面存在局限性，但它在转移性乳腺癌的反应评估中发挥着关键作用。进一步的 PET 放射性药物已被提出来满足这些临床需求。FES PET/CT 证明了其在评估 ER 表达和预测管腔乳腺癌治疗反应方面的有用性，对治疗优化和监测具有重要意义。在 HER2 阳性和 HER2 低乳腺癌中，HER2 靶向 PET 示踪剂显示出评估 HER2 状态的潜力，但其预测靶向治疗反应的准确性仍存在争议。 PARP 靶向 PET 成像有潜力选择接受 PARP 抑制剂治疗的患者，特别是在三阴性乳腺癌 (TNBC) 中，由于缺乏特定靶标，成像工具至关重要。免疫疗法和抗体药物偶联物 (ADC) 是 TNBC 的新兴治疗选择，而针对免疫检查点的 PET 成像可以帮助治疗选择和反应监测。 PET/CT 成像在定制乳腺癌治疗中的动态作用需要进一步的多学科研究来验证靶向示踪剂的临床效用。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

There is a critical need for timely and accurate decisions in breast cancer management. This narrative review aims to clarify the potential role of novel PET tracers in optimizing treatment strategies for different breast cancer subtypes.2-deoxy-2-[18F]-fluoro-D-glucose PET/computed tomography (FDG PET/CT) has a pivotal role in response assessment in metastatic breast cancer, despite its limitations in certain histological and molecular subtypes. Further PET radiopharmaceuticals have been proposed to address these clinical needing.FES PET/CT demonstrates its usefulness in assessing ER expression and predicting response to therapy in luminal breast cancer, with implications for treatment optimization and monitoring. In HER2-positive and HER2-low breast cancer, HER2-targeted PET tracers show potential in assessing HER2 status, while their accuracy in predicting response to targeted therapies is still debated. PARP-targeted PET imaging holds potential for selecting patients for PARP inhibitors treatments, particularly in triple-negative breast cancer (TNBC), where imaging tools are crucial due to the absence of specific targets. Immunotherapy and antibody-drug conjugates (ADCs) are emerging treatment options for TNBC, and PET imaging targeting immune checkpoints could aid in treatment selection and response monitoring. The dynamic role of PET/CT imaging in tailoring breast cancer treatments requires further multidisciplinary research to validate the clinical utility of targeted tracers.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.